PRESS RELEASE: 'The Corporate Reputation of Pharma, 2018 - the Perspective of Mental-Health Patient Groups' 'The Corporate Reputation of Pharma in 2018 - the Perspective of 100 Mental-Health Patient Groups' ~ Contact: Alex Wyke ~ Tel: +44-(0)7960-855-019 ~ Email: report@patient-view.com EMBARGO: London, September 30th, 2019 6AM GMT ABOUT THIS REPORT AND SURVEY
Allergan I AstraZeneca I Biogen I Boehringer Ingelheim I Bristol-Myers Squibb I Eli Lilly I GSK I Janssen I Lundbeck I Otsuka I Pfizer I Roche/Genentech I Sanofi I Takeda/Shire I and Teva. KEY FINDINGS ACROSS THE PHARMA INDUSTRY Percentage of respondent mental-health patient groups stating that the corporate reputation of the pharmaceutical industry as a whole was “Excellent” or “Good”, 2015-2018 The attitudes of mental-health patient groups towards the pharmaceutical industry have fluctuated over the four years that PatientView has been analysing their viewpoints; but, overall, mental-health patient groups are becoming less positive about the industry’s corporate reputation. In 2015, 38% of respondent mental-health patient groups stated that the industry had an “Excellent” or “Good” corporate reputation; in 2018, the equivalent figure was down to just 24%. Much appears to hinge on the pharma industry’s R&D output in the therapy area. 2015’s respondent mental-health patient groups were far more confident than those of 2018 that pharma had the ability to innovate, and to produce high-quality products of value to people with a mental-health condition. As many as 67% of the 2015 respondents thought pharma “Excellent” or “Good” at innovation, and 73% said the same for pharma’s ability to provide high-quality products. In 2018, those figures had fallen to 27% and 39% respectively. These negative views on pharma R&D dominate mental-health patient groups’ thinking about the pharmaceutical industry today. Yet, despite the generally gloomy opinions, a small number of 2018’s respondent mental-health patient groups did comment very favourably on recent initiatives taken by some pharmaceutical companies to deliver both new products, and new approaches, in the therapy area. Percentage of respondent patient groups stating each year that the pharmaceutical industry was “Excellent” or “Good” at two activities of importance to these patient groups: innovation and the provision of high-quality products; mental health v. all therapy areas HOW DID COMPANIES PERFORM? Despite being recognised by respondent mental-health patient groups, not all of the 15 companies included in this analysis have significant levels of engagement with these patient groups. The companies that do are: Eli Lilly; Janssen; Lundbeck; and Otsuka. Several years ago, many more companies used to work with mental-health patient groups. Back in 2015, PatientView’s survey reported active engagement by the following eight additional companies: AbbVie; Boehringer Ingelheim; Bristol-Myers Squibb; GSK; Merck & Co/MSD; Pfizer; Roche/Genentech; and Sanofi. As the PharmaTimes remarked in a May 2019 article on the pharmaceutical-industry’s involvement in mental health: “There has been a shift away from developing new drugs for mental-health disorders, despite the massive health burden they create, and the fact that they are potentially growing even more prominent.”[http://www.pharmatimes.com/web_exclusives/big_pharma_-_come_back_to_mental_health_and_invest_in_europe_1287736] Mental-health patient groups' familiarity, and partnerships, with pharma companies, 2018. Number of respondent mental-health patient groups. * Includes ‘worked with’ HOW CORPORATE REPUTATION IS MEASURED The overall corporate reputation of each company is assessed according to that company's performance (as judged by mental-health patient groups) at 12 individual indicators of corporate reputation. The RANKINGS of 15 companies for corporate reputation—from the perspective of mental-health patient groups familiar with the company, 2018 v. 2017 The indicators [listed below] have been developed over the years by PatientView, drawing on recommendations from patient groups, health professionals, health regulators, and industry. PatientView's 12 indicators used to assess pharma corporate reputation
-END OF PRESS RELEASE- For further information on the 2018 MENTAL-HEALTH report, please use contact details at the top of this press release
|